vs

Side-by-side financial comparison of Coya Therapeutics, Inc. (COYA) and Versus Systems Inc. (VS). Click either name above to swap in a different company.

Coya Therapeutics, Inc. is the larger business by last-quarter revenue ($4.0M vs $2.2M, roughly 1.8× Versus Systems Inc.).

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative regulatory T cell (Treg)-based therapies to address unmet medical needs for patients with neurodegenerative, autoimmune, and inflammatory diseases. Its core pipeline includes lead candidates targeting conditions like amyotrophic lateral sclerosis, with primary planned commercial markets across North America and the European Union.

Versus Systems Inc. operates a proprietary interactive reward platform that integrates with video games, streaming content, live sports broadcasts and mobile apps. It enables content creators and brands to offer personalized real-time prizes to audiences across North America and global digital entertainment markets.

COYA vs VS — Head-to-Head

Bigger by revenue
COYA
COYA
1.8× larger
COYA
$4.0M
$2.2M
VS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
COYA
COYA
VS
VS
Revenue
$4.0M
$2.2M
Net Profit
$-964.9K
Gross Margin
0.2%
Operating Margin
-54.2%
Net Margin
-44.7%
Revenue YoY
202768.8%
Net Profit YoY
-95.8%
-19.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
COYA
COYA
VS
VS
Q4 25
$4.0M
$2.2M
Q3 25
$3.6M
$0
Q2 25
$-176.0K
Q4 24
$0
Q3 24
$0
Q2 24
$3.4M
Q2 23
$157.9K
Q3 22
$316.8K
Net Profit
COYA
COYA
VS
VS
Q4 25
$-964.9K
Q3 25
$-2.1M
$-537.8K
Q2 25
$672.3K
Q4 24
$-809.5K
Q3 24
$-4.0M
Q2 24
$-2.9M
Q2 23
$-2.3M
Q3 22
$-3.5M
Gross Margin
COYA
COYA
VS
VS
Q4 25
0.2%
Q3 25
Q2 25
Q4 24
Q3 24
Q2 24
Q2 23
79.5%
Q3 22
Operating Margin
COYA
COYA
VS
VS
Q4 25
-54.2%
Q3 25
-68.3%
Q2 25
Q4 24
Q3 24
Q2 24
-94.5%
Q2 23
-840.1%
Q3 22
Net Margin
COYA
COYA
VS
VS
Q4 25
-44.7%
Q3 25
-59.4%
Q2 25
-382.0%
Q4 24
Q3 24
Q2 24
-84.4%
Q2 23
-1462.9%
Q3 22
-1107.9%
EPS (diluted)
COYA
COYA
VS
VS
Q4 25
Q3 25
$-0.13
Q2 25
$0.14
Q4 24
$-0.27
Q3 24
$-0.26
Q2 24
$-0.19
Q2 23
$-2.41
Q3 22
$-1.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
COYA
COYA
VS
VS
Cash + ST InvestmentsLiquidity on hand
$46.8M
$527.4K
Total DebtLower is stronger
Stockholders' EquityBook value
$43.0M
$10.2M
Total Assets
$50.0M
$2.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
COYA
COYA
VS
VS
Q4 25
$46.8M
$527.4K
Q3 25
$28.1M
Q2 25
Q4 24
$3.1M
Q3 24
$31.1M
Q2 24
$36.6M
Q2 23
$3.2M
Q3 22
$1.0M
Stockholders' Equity
COYA
COYA
VS
VS
Q4 25
$43.0M
$10.2M
Q3 25
$27.3M
$11.1M
Q2 25
$11.7M
Q4 24
$11.4M
Q3 24
$32.0M
Q2 24
$35.3M
Q2 23
$6.4M
Q3 22
$14.1M
Total Assets
COYA
COYA
VS
VS
Q4 25
$50.0M
$2.1M
Q3 25
$32.0M
$3.1M
Q2 25
$3.8M
Q4 24
$3.5M
Q3 24
$35.6M
Q2 24
$39.9M
Q2 23
$9.5M
Q3 22
$17.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
COYA
COYA
VS
VS
Operating Cash FlowLast quarter
$-10.7M
$-568.6K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
COYA
COYA
VS
VS
Q4 25
$-10.7M
$-568.6K
Q3 25
$-1.1M
$24.7K
Q2 25
$-867.5K
Q4 24
$-716.6K
Q3 24
$-5.5M
Q2 24
$-4.6M
Q2 23
$-1.3M
Q3 22
$-1.7M
Cash Conversion
COYA
COYA
VS
VS
Q4 25
Q3 25
Q2 25
-1.29×
Q4 24
Q3 24
Q2 24
Q2 23
Q3 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons